Controversies in dyslipidemias: Atheroprevention in diabetes and insulin resistance

Annals of the New York Academy of Sciences

Volumn 1055, Issue , 2005, Pages 159-178

  Brinton, Eliot A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Atherogenesis; Cardiac risk factors; Cardiovascular disease; Diabetes; Estrogen; Glucose tolerance; Inflammation; Insulin resistance; Lipids; Lipoproteins; Metabolic syndrome; Obesity; Statins; Trigylcerides

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAMIPRIL; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; RISK FACTOR;

EID: 32244442963     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1323.024     Document Type: Conference Paper

References (24)

1. STAMLER, J., O. VACCARO, J.D. NEATON & D. WENTWORTH. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. 16: 434-444.
2. MCCARTNEY, P., H. KEEN & R. JARRETT. 1983. The Bedford Study: observations on retina and lens of subjects with impaired glucose tolerance and in controls with normal glucose tolerance. Diabetes Metab. 9: 303-305.
3. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
4. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl. J. Med. 342: 145-153.
5. HAFFNER, S.M. et al. 1998. Mortality in coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 339: 229-234.
6. HEART PROTECTION STUDY COLLABORATIVE GROUP. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22.
7. LAROSA, J.C. et al. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl. J. Med. 352: 1424-1435.
8. MCMAHON, M. et al. 2000. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metabl. Cardiovasc. Dis. 10: 195-203.
9. PETER, S. et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. Lancet 361: 1149-1158,
10. COLHOUN, H.M. et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
11. SERRUYS, P.W. et al. 2002. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 287: 3215-3222.
12. DOWNS, J.R. et al. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279: 1615-1622.
13. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 344: 1383-1389.
14. BROWN, B.G. et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New. Engl. J. Med. 345: 1583-1595.
15. FRICK, M.H. et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl. J. Med. 317: 1237-1245.
16. RUBINS, H.B. et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl. J. Med. 341: 410-418.
17. DIABETES ATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS. 2001. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905-910.
18. See http://www.accordtrial.org.
19. THE CORONARY DRUG PROJECT RESEARCH GROUP. 1975. Clofibrate and niacin in coronary heart disease. JAMA 231: 360-381.
20. CANNER, P.L. et al. 2005. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 15: 254-257.
21. MIETTINEN, T.A. et al. 1998. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Br. Med. J. 316: 1127-1130.
22. KANAYA, A.M. et al. 2003. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study: A randomized, double-blind, placebo-controlled trial. 2003. Ann. Intern. Med. 138: 1-9.
23. HULLEY, S. et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopasual women. JAMA 280: 605-613.
24. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.